Kyle Richards, MD
Urology · Madison, WINPI 1356524805
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,915 of the $8,514 with a category attached, or 93.0%. F. Hoffmann-la Roche AG accounts for 64.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $5,777 and has fallen 96.3% since, to $217 in 2025. Among urology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 11 payments — averaging $774.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$6K
- Urogen Pharma, Inc.$2K
- Photocure Inc$169
- Ferring Pharmaceuticals Inc.$144
- Dendreon Pharmaceuticals LLC$107
- Genentech, Inc.$93
- plus $86 from 2 others
What the payments were for
- Speaking & faculty fees$7,91593%
- Food & beverage$5997%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 2 | $5,515 |
| Urogen Pharma, Inc. | 1 | $2,400 |
| Photocure Inc | 2 | $169 |
| Ferring Pharmaceuticals Inc. | 2 | $144 |
| Dendreon Pharmaceuticals LLC | 1 | $107 |
| Genentech, Inc. | 1 | $93 |
| Johnson & Johnson | 1 | $72 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECENTRIQ$5,515
- ADSTILADRIN$108
- PROVENGE$107
How this compares
$8,514 in reported general payments places this provider in the 90th percentile of 215 urology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 65 | $1,271 |
| Trimethoprim | 27 | $861 |
| Solifenacin Succinate | 15 | $384 |
| NitrofurantoinNitrofurantoin Macrocrystal | 12 | $259 |
| Finasteride | 13 | $245 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $241 |
| Ciprofloxacin Hcl | 30 | $67 |
Paid to pharmacies, not to this prescriber.
Other urology in Madison
- Dan GralnekMadison$142K
- Christopher ManakasMadison$87K
- Javier SantiagoMadison$57K
- Margaret KnoedlerMadison$31K
- Edwin AbelMadison$22K
- Stephen NakadaMadison$11K
- Reginald BruskewitzMadison$8K
- Sara BestMadison$7K
- Daniel RoadmanMadison$5K
- Ali AntarMadison$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.